R&D trend #5: The top ex­ecs in biotech are rid­ing a boom — but there’s one big step left

Over the past few months I’ve been en­joy­ing watch­ing some se­r­i­al en­tre­pre­neurs dou­bling down on their ex­per­tise. Greg Ver­dine called re­cent­ly about his sec­ond on­go­ing start­up and launch round and Michael Gilman talked up his plans to hatch an­oth­er com­pa­ny as the first A round on his third biotech start­up was rolling out.

These days, drug de­vel­op­ment is more project ori­ent­ed than ever. Small teams un­der an ex­pe­ri­enced guid­ing hand can ac­com­plish a lot. They are tai­lor-made for nail­ing down proof-of-con­cept da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER